お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
980135

選択的エストロゲン受容体分解薬(SERD):市場・投与量・価格・臨床試験の考察 (~2025年)

Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025

出版日: | 発行: KuicK Research | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

選択的エストロゲン受容体分解薬(SERD):市場・投与量・価格・臨床試験の考察 (~2025年)
出版日: 2021年01月06日
発行: KuicK Research
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界における選択的エストロゲン受容体分解薬(SERD)の市場規模は、2025年までに20億米ドルを上回る見込みです。世界のSERD市場は、今後数年間で2桁のCAGRで成長すると予測されています。治療薬市場の主要な促進要因は、米国市場および新興市場であると推定されています。

治療薬市場の現在の研究開発パイプラインは驚異的な速度で成長しており、市場の成功率は歴史的なレベルで加速しているため、今後数年間で潜在的な候補薬の立ち上げが増えることが見込まれます。選択的エストロゲン受容体療法市場で承認された将来の新製品は、市場ブランドが大幅に成長するため、大きな純売上高と収益創出に寄与すると考えられています。

当レポートでは、選択的エストロゲン受容体分解薬(SERD)市場について調査し、企業・国・適応症・患者セグメント別による臨床パイプラインの考察、ブランド医薬品・ジェネリック医薬品の投与量・価格・売上に関する考察、および商業的機会・臨床的機会の考察などを提供しています。

目次

第1章 選択的エストロゲン受容体分解薬(SERD)のイントロダクション

  • 概要
  • SERDの進化

第2章 選択的エストロゲン受容体分解薬:作用機序

第3章 併用療法としての選択的エストロゲン受容体阻害剤

  • CDK4/6阻害剤とSERDの併用
  • PI3K阻害剤とSERDの併用
  • アロマターゼ阻害剤とSERDの併用
  • mTOR阻害剤とSERDの併用

第4章 がん治療におけるSERDの役割

第5章 乳がんにおける選択的エストロゲン受容体分解薬

  • 乳がん治療におけるSERDの影響
  • 進行中の研究開発
    • AZD 9833
    • Rintodestrant(G1T48)
    • ZN-c5
    • Elacestrant(RAD1901)
    • LSZ 102
    • OP-1250
    • LY3484356
    • GDC-9545(RG6171)
    • SHR9549
    • AZD9496

第6章 選択的エストロゲン受容体分解薬市場の分析

  • 現在の市場シナリオ
  • 選択的エストロゲン受容体分解薬市場に対するCOVID-19の影響
  • 市場機会

第7章 選択的エストロゲン受容体分解薬:市場動向

  • ZentalisPharmaはEliLilyと協力して、SERDとCDK4 / 6阻害剤の組み合わせを評価
  • Olema Oncology & NovartisがSERDを併用療法として評価するための臨床協力を発表
  • 新しいSERD併用療法は、HR + / HER2陰性乳がんに対して有望な結果を示す
  • RadiusとMenariniがElacestrantの開発と商品化のために協力
  • SERDの組み合わせは、乳がんを治療するための神経線維腫症遺伝子を標的にすることが可能

第8章 選択的エストロゲン受容体分解薬(SERD)阻害剤の臨床試験の概要

  • 企業別
  • 適応症別
  • 患者セグメント別
  • フェーズ別

第9章 選択的エストロゲン受容体分解薬(SERD)の臨床試験の考察

  • 前臨床
  • フェーズI
  • フェーズI / II
  • フェーズII
  • フェーズIII

第10章 市販の選択的エストロゲン受容体分解薬(SERD)の考察:フルベストラント

第11章 Faslodex(フルベストラント):市販の選択的エストロゲン受容体阻害薬

  • 承認と特許紛争
  • 価格と投与量の分析
  • 売上分析
  • Faslodex:償還シナリオ

第12章 フルベストラントのジェネリック医薬品:可用性&価格分析

  • フルビグレン
  • フルベナート
  • フルベトラズ
  • フベステロール
  • ストランタス
  • セルベストラント
  • ファスロマックス
  • ファスノルム

第13章 競合情勢

  • AsteraZeneca
  • Eli Lilly
  • G1 Therapeutics
  • Novartis
  • Olema Oncology
  • Radius Therapeutics
  • Roche
  • Sage Therapeutics
  • Zeno Pharma
  • Zentalis
図表

List of Figures

  • Figure 1-1: Evolution of SERDs Drugs
  • Figure 2-1: Role of Estrogen Receptor in Tumor Development
  • Figure 2-2: Mechanism of Selective Estrogen Receptor Degraders
  • Figure 2-3: Mechanism of SERDs in Combination with other Cancer Therapeutics
  • Figure 3-1: CDK 4/6 Inhibitors Used in Combination with SERDs
  • Figure 3-2: PI3K Inhibitors Used in Combination with SERDs
  • Figure 3-3: Aromatase Inhibitors Used in Combination with SERDs
  • Figure 4-1: Global - Breast Cancer Cases by Nature of Estrogen Receptor (%), 2020
  • Figure 4-2: Role of SERDs in Cancer Management
  • Figure 5-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 5-2: Global - Breast Cancer Cases by Type (Million), 2020
  • Figure 5-3: Investigational SERDs Candidates & Their Manufacturers
  • Figure 5-4: SERENA-2 Trial - Study Initiation & Expected Completion Year For Primary Breast Cancer
  • Figure 5-5: SERENA-2 Trial - Study Initiation & Expected Completion Year for Advanced Breast Cancer
  • Figure 5-6: SERENA-1 Trial - Study Initiation & Expected Completion Year
  • Figure 5-7: AZD9833 Japan Trial - Study Initiation & Expected Completion Year
  • Figure 5-8: Rintodestrant Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-9: ZN-c5 Monotherapy Trial - Study Initiation & Expected Completion Year
  • Figure 5-10: ZN-c5/Abemaciclib Combination Trial- Study Initiation & Expected Completion Year
  • Figure 5-11: ZN-c5/ Palbociclib Trial- Study Initiation & Expected Completion Year
  • Figure 5-12: Elacestrant Phase 3 Trial- Study Initiation & Expected Completion Year
  • Figure 5-13: Elacestrant - Study Initiation & Completion Year
  • Figure 5-14: LSZ102 Phase I/II Trial- Study Initiation & Completion Year
  • Figure 5-15: OP-1250 Phase I/II Trial - Study Initiation & Completion Year
  • Figure 5-16: EMBER-2 Trial - Study Initiation & Expected Completion Year
  • Figure 5-17: LY3484356 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-18: GDC-9545 Phase I Trial- Study Initiation & Expected Completion Year
  • Figure 5-19: GDC-9545/Fulvestrant Combinational Trial - Study Initiation & Expected Completion Year
  • Figure 5-20: SHR 9549 Phase I Trial - Study Initiation & Completion Year
  • Figure 6-1: Global - SERD Market Size (US$ Million), 2016 - 2020
  • Figure 6-2: Global - SERD Market Size by Type of Product (US$ Million), 2019
  • Figure 6-3: Global - SERD Market Size by Type of Product (%), 2019
  • Figure 6-4: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity, 2020
  • Figure 6-5: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity (%), 2020
  • Figure 6-6: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-7: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-8: Global - Estimated ER Positive Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-9: Global - SERD Market Opportunity (US$ Billion), 2020 - 2025
  • Figure 6-10: US - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 6-11: Europe - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 8-1: SERD - Clinical Trials by Company (Number of Drugs), 2020 - 2025
  • Figure 8-2: SERD - Clinical Trials by Indication (Number of Drugs), 2020 - 2025
  • Figure 8-3: SERD - Clinical Trials by Patient Segment (Number of Drugs), 2020 - 2025
  • Figure 8-4: SERD - Clinical Trials by Phase (Number of Drugs), 2020 - 2025
  • Figure 11-1: Faslodex - FDA Approval Year by Type of Breast Cancer
  • Figure 11-2: Faslodex - FDA Approval Year & First Generic Approval Year
  • Figure 11-3: Faslodex - Patent Issue & Expiration Year
  • Figure 11-4: Faslodex - Price for 10 ml & Price per ml of Intramuscular Injection (US$), January'2021
  • Figure 11-5: Faslodex - Recommended & Reduced Dose (mg)
  • Figure 11-6: Faslodex - Number of Doses by Treatment Phase
  • Figure 11-7: Faslodex - Cost For First & Subsequent Treatment Cycle (US$)
  • Figure 11-8: Global - Faslodex Annual Sales Value (US$ Million), 2016 - 2019
  • Figure 11-9: Global - Faslodex Annual Sales Values (US$ Million), 2002 - 2015
  • Figure 11-10: Global - Faslodex Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 11-11: US - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-12: Europe - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-13: Global - Faslodex Annual Sales Value by Region (US$ Million), 2019
  • Figure 11-14: Global - Faslodex Annual Sales Value by Region (%), 2019
  • Figure 11-15: Global - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-16: Global - Faslodex 9 Month Sales Value by Region (US$ Million), 2020
  • Figure 11-17: Global - Faslodex 9 Month Sales Value by Region (%), 2019
  • Figure 11-18: US - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-19: Europe - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-20: US - Typical Co-Pay Range of Branded & Generic Fulvestrant (US$), January'2021
  • Figure 12-1: Fulviglen - Price for a Supply of 3 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-2: Fulviglen - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-3: Fulviglen - Price for a Supply of 9 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-4: Fulvenat - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-5: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-6: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-7: Fulvetraz - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-8: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-9: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-10: Fuvesterol - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-11: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-12: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-13: Strantas - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-14: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-15: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-16: Celvestrant - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-17: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-18: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-19: Faslomax - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-20: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-21: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-22: Fasnorm - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-23: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-24: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
目次

"Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

  • Global SERD Market Opportunity: > US$ 2 Billion By 2025
  • USA To dominate Global SERD Market
  • SERD In Clinical Trials: > 15 Drugs
  • Detailed Clinical insight on All Drugs in clinical Trials
  • Clinical Pipeline Insight by Company, Country, Indication & Patient Segment
  • Branded & Generic Drug Dosage, Price & Sales Insight
  • 150 Page Report: Commercial & Clinical Opportunity Insight

The research report, "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" provides detailed insight on clinical and non clinical parameters involved in the development and expansion of the global SERD market. In addition to it, the research report also describes the impact of novel drug launches on the other available therapies for breast cancer as well as growth rate of the specific drugs available under the therapy. Other than the market forecast, the research report also highlights the future trends and opportunities that will highly impact the use of expensive drugs for the treatment of breast cancer. Some of the areas that are highlighted in the research report involves the market fragmentation based on the real-world evidence of the therapy at clinical and pre-clinical level.

The global selective estrogen receptor degrader therapy market is witnessed to exceed by a double-digit CAGR rate over the next few years, which will positively impact the other commercially available therapies and cause a notable slowdown in their market growth rate. The major key drivers for the therapy market are estimated to be the US market as well as emerging markets upto some extent, which in the future years will also continue to be the major drivers for the market. The current research and development pipeline for the therapy market is growing at a splendid rate, and the success rate for the market are accelerating at historic level, thus resulting in more launches of potential candidates in the upcoming years. The future novel products approved under selective estrogen receptor degrader therapy market are believed to contribute a large net sales and revenue generation, as the market brand will grow at extensive rate.

The current market is observed to lift the share of the oncology sector to the global pharmaceutical market to new extent, which will continue to increase with time. In addition to it, the overall market at global level has also observed a large influx in the number of market players and government initiatives so that large number of patients could receive benefits from such selective cancer therapy. The highly advanced satisfactory applications and benefits received from the therapy is believed to expand the market to become one standard care for patients suffering from breast cancer.

As per the research conducted for Global selective estrogen receptor degrader therapy market, it is estimated that the therapy when compared with other commercially available therapies can provide maximum potential returns to the breast cancer patients in terms of healthcare benefits as well as to the investors and bio-pharmaceutical companies in terms of total sales and revenue generation. The market due to strong and robust clinical pipeline is also brewing up to become more independently and economically strong. It is observed for the market, that the long-term healthcare benefits available will push the researchers towards conducting more complex clinical research studies in order to generate more applications for the breast cancer patients.

Table of Contents

1. Introduction to Selective Estrogen Receptor Degraders (SERDs)

  • 1.1 Overview
  • 1.2 Evolution of SERDs

2. Selective Estrogen Receptor Degraders - Mechanism of Action

3. Selective Estrogen Receptor Inhibitors as Combinational Therapy

  • 3.1 SERD with CDK 4/6 Inhibitors
  • 3.2 SERD with PI3K Inhibitors
  • 3.3 SERD with Aromatase Inhibitors
  • 3.4 SERDs with mTOR Inhibitors

4. Role of SERDs in Cancer Treatment

5. Selective Estrogen Receptor Degraders in Breast Cancer

  • 5.1 Impact of SERDs in Breast Cancer Treatment
  • 5.2 Ongoing Research & Development
    • 5.2.1 AZD 9833
    • 5.2.2 Rintodestrant (G1T48)
    • 5.2.3 ZN-c5
    • 5.2.4 Elacestrant (RAD1901)
    • 5.2.5 LSZ 102
    • 5.2.6 OP-1250
    • 5.2.7 LY3484356
    • 5.2.8 GDC-9545 (RG6171)
    • 5.2.9 SHR9549
    • 5.2.10 AZD9496

6. Selective Estrogen Receptor Degrader Market Analysis

  • 6.1 Current Market Scenario
  • 6.2 Impact of COVID-19 on Selective Estrogen Receptor Degrader Market
  • 6.3 Market Opportunity

7. Selective Estrogen Receptor Degrader - Market Trends

  • 7.1 Zentalis Pharma Collaborated with Eli Lily to Evaluate the Combination of SERD with CDK4/6 Inhibitors
  • 7.2 Olema Oncology & Novartis Announces Clinical Collaboration to Evaluate SERD as Combinational Therapy
  • 7.3 New SERD Combinational Therapy Shows Promising Results against HR+/HER2 Negative Breast Cancer
  • 7.4 Radius & Menarini Collaborates for Development & Commercialization of Elacestrant
  • 7.5 SERD Combination Can Target the Neurofibromatosis Gene for Treating Breast Cancer

8. Selective Estrogen Receptor Degrader (SERD) Inhibitors Clinical Trials Overview

  • 8.1 By Company
  • 8.2 By Indication
  • 8.3 By Patient Segment
  • 8.4 By Phase

9. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight

  • 9.1 Preclinical
  • 9.2 Phase-I
  • 9.3 Phase-I/II
  • 9.4 Phase-II
  • 9.5 Phase-III

10. Marketed Selective Estrogen Receptor Degrader (SERD) Insight: Fulvestrant

11. Faslodex (Fulvastrant)- Commercially Available Selective Estrogen Receptor Inhibitor Drug

  • 11.1 Approval & Patent Dispute
  • 11.2 Pricing & Dosage Analysis
  • 11.3 Sales Analysis
  • 11.4 Faslodex - Reimbursement Scenario

12. Generic Fulvestrant - Availability & Price Analysis

  • 12.1 Fulviglen
  • 12.2 Fulvenat
  • 12.3 Fulvetraz
  • 12.4 Fuvesterol
  • 12.5 Strantas
  • 12.6 Celvestrant
  • 12.7 Faslomax
  • 12.8 Fasnorm

13. Competitive Landscape

  • 13.1 AsteraZeneca
  • 13.2 Eli Lilly
  • 13.3 G1 Therapeutics
  • 13.4 Novartis
  • 13.5 Olema Oncology
  • 13.6 Radius Therapeutics
  • 13.7 Roche
  • 13.8 Sage Therapeutics
  • 13.9 Zeno Pharma
  • 13.10 Zentalis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.